메드팩토

235980KOSDAQ

51.0 / 100

Reference Date: 2026-10-23

Financial Score17.5 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 13.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Medfact is a biotech company established in 2013, specializing in the development of innovative drugs for refractory cancers using advanced genomic analysis technology. Its flagship product, Vactosertib, targets the TGF-β1 signaling pathway to modulate the tumor microenvironment and enhance the efficacy of existing cancer treatments when used in combination. The company is currently conducting clinical trials for various cancers, including colorectal, pancreatic, and osteosarcoma.

Number of Employees

54people

Average Salary

57.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.39Industry Average 1.201.0Point

2.0x industry avg (risky)

ROE

-24.70Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

2.86Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

3.0 / 3

Avg ▲29.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.5% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 3,205Won52-week high 8,05052-week low 2,240

1-month return5.0Point

1m +13.45% (rising)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항(임상시험계획변경승인) (재발성, 불응성 또는 진행성 골육종 환자 대상 백토서팁 단독 요법 제1/2상 임상시험계획(IND) 미국 식품의약국(FDA) 변경 승인)2026-10-19
Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (MP2021 호주 임상1상 시험 계획 승인)2026-10-02